Navigation Links
Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis

HAE:TSX

MONTREAL, June 14, 2007 /PRNewswire-FirstCall/ Haemacure Corporation , a Montreal-based specialty biotherapeutics company, today announced the preliminary findings of the content analysis of one of its plasma discards.

Preliminary findings confirm the presence of a number of proteins and enzymes with applications in significant worldwide markets, including albumin, plasminogen, immunoglobulin and A1PI.

These findings take on a strategic significance for Haemacure as revenues eventually generated from the commercial exploitation of these proteins and enzymes will constitute a direct contribution to the bottom line. This is because the cost of the plasma will be fully borne by Haemacure's fibrin sealant and hemostatic agent once these products will be commercialized.

"We are very excited with the positive outcome of the content analysis of one of our plasma discards," said Joseph Galli, Chairman and Chief Executive Officer of Haemacure. "This is the first tangible result of our new biotherapeutics orientation that we announced at our recent meeting of shareholders. The identification of these proteins and enzymes indicates that our patented plasma protein extraction technology yields significant potential benefits superior to the traditional extraction technology. With these results in hand, and further to interest expressed by third parties in our plasma discard, we will drive towards implementing our business development strategy that encompasses partnerships with pharmaceutical and biotechnology companies." concluded Mr. Galli.

Haemacure plans on harvesting albumin from this discard and using it in the production of its fibrin sealant, representing annual cost savings estimated at more than US$500,000 at full production plant capacity. Some albumin extracted could also be available for commercialization.

According to the Marketing Research Bureau, the world pla
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... Sustained Improvements in Blood Glucose,Control and Progressive ... /PRNewswire-FirstCall/ -- Amylin,Pharmaceuticals, Inc. and Eli Lilly ... that showed BYETTA(R) (exenatide) injection,sustained improvements in ... three and a half years of therapy. ...
... 25, 2007 /PRNewswire-FirstCall/ --,Phosphagenics Limited (AIM: PSG) announced ... dermal drug delivery,technology formulated with retinoic acid, a ... ingredient used in,anti-aging cosmetics. , The proof of ... of retinoic acid delivered into the skin when ...
Cached Medicine Technology:Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6Phosphagenics Announces Positive Proof of Concept Results from,Studies Utilizing Company's Dermal Drug Delivery Technology 2
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... non-cancerous prostate tissue may have nearly twice the risk ... inflammation, according to results of a new study led ... , The link between persistent inflammation and cancer was ... those with a Gleason score between 7 and ... and rapidly growing prostate cancers. , "What we,ve shown ...
(Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... ... ... ... ...
... ... ... ... ...
... compared traditional surgery with less-invasive stenting to clear dangerously ... "seminal and robust." The Carotid Revascularization Endarterectomy vs. ... of both procedures are roughly equal. The trial, conducted ... the largest randomized stroke prevention trials ever. Loyola ...
... ... Conducts Statewide Outreach Efforts to Provide Low-Income Children Access to Dental Care ... ... Month draws to a close, California’s dental hygienists are reminding parents and ...
... 12,000 years ago, researchers say, , FRIDAY, Feb. 26 (HealthDay ... East more than 12,000 years ago, new research suggests. , ... IGF1 is a major determinant of small size in dogs. ... domestication of the Middle Eastern gray wolf, according to the ...
... evidence that newcomers hold mettle against warfarin, aspirin , ... more proof that the mainstays of anti-clotting therapy, namely ... newcomers. , Researchers presenting their findings during a ... meeting in San Antonio show that one new drug, ...
Cached Medicine News:Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 2Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 3Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 4Health News:American National Announces Corrected Dividend Dates 2Health News:Stents as good as surgery for clogged carotid arteries 2Health News:California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort 2Health News:California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort 3Health News:Current Blood Thinners Face Tough Competition 2Health News:Current Blood Thinners Face Tough Competition 3
... of infrared laser photocoagulators includes the OcuLight ... lasers serve as a single laser source ... no regular maintenance or special electrical/cooling, and ... The OcuLight SLx is now available with ...
The simplest, most accurate Ortho-K lens fitting system ever!...
... permeable contact lenses used for corneal refractive ... (myopia). The patient wears the lenses overnight ... During the day, nearsightedness is corrected or ... RG contact lenses apply slight pressure to ...
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
Medicine Products: